19-22 October 2022
Posted at h
in News
19th International Celiac Disease Symposium, Sorrento, Italy. Jos Houbiers, Chief Medical Officer of calypso Biotech, gives a lecture entitled “Interim results from an in-human study of an anti-IL-15 antibody for treating celiac disease” ...
28 September – 01 October 2022
Posted at h
in News
51st European Society for Dermatological Research meeting, Amsterdam, the Netherlands. Calypso Biotech and Monasterium present a poster entitled “Interleukin-15 inhibition ameliorates atopic dermatitis lesions experimentally induced in xenotransplanted human skin” ...
20 May 2022: Calypso Biotech supports EUREOS
Posted at h
in News
EUREOS is the European association for clinicians and researchers to share knowledge on Eosinophilic Esophagitis. http://eureos.online...
20 February 2019: Calypso Biotech BV secures 20 Million EUR in Series A Financing and Strengthens Team to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases.
Posted at h
in Press release
Click to see full press release...
19 February 2019: AGC Biologics A/S and Calypso Biotech BV Announce Agreement for Process Development and cGMP Manufacture of CALY-002
Posted at h
in Press release
Click to see full press release...
31 March 2017: Calypso Biotech licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharma
Posted at h
in Press release
Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.